Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Kestra Medical Technologies, Ltd. KMTS

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$95.1M
▲ 59.0% YoY
$-131.6M
$-116.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Its Cardiac Recovery System platform is anchored by the ASSURE Wearable Cardioverter Defibrillator, which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. As of April 30, 2026, its ASSURE WCD had protected nearly 40,000 patients since its commercial launch. As of April 30, 2026, it had over 443 full time team members, substantially all of whom are located in the U.S. Its principal office is located at 3933 Lake Washington Blvd Northeast, Suite 200, Kirkland, Washington.

Written from the business description in KESTRA MEDICAL TECHNOLOGIES, LTD.'s annual report to the U.S. Securities and Exchange Commission, filed 14 July 2026. Every sentence was checked against that document before publication.

Growth

USD 95.1M
Revenue, FY2025 · full 3-year series below
Revenue $M Net income $M
FY2025 · Revenue 95.1 · Net income -131.6
40M80M-50M-100M
202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−138 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -141.6% · Net -138.4%
-100%-200%-300%
202320242025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Gross margin51.4%
Operating margin-141.6%
Net margin-138.4%
EBITDAUSD -126.0M

Each USD of equity lost 57 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -116.6
-50M-100M
202320242025

Total assetsUSD 358.5M
CashUSD 99.7M
Gross debtUSD 42.6M
Net debtUSD -57.1M
Current ratio4.41×

Net debt stands at -22% of equity.

The 3-year record

3 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
KMTS, 3-year financial record
Metric 202520242023
Revenue $B0.10.10.0
Operating income $B−0.1−0.1−0.1
EBITDA $B−0.1−0.1−0.1
Income tax $B0.00.00.0
Net income $B−0.1−0.1−0.1
Free cash flow $B−0.1−0.1−0.1
EPS, diluted $−2.43−5.13−5.07
Dividend / sh $◌◌◌
Payout % — not applicable: no dividend———
ROE %−56.6——
Shares out B0.060.050.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 15 reconciliationsAUDITED

Reconciled in 3 of the 3 fiscal years we could check. 32 checks were skipped: the balance sheet is not tagged before 2023. 16 checks were skipped: EPS is not tagged before 2023. 16 checks were skipped: revenue is not tagged before 2023.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code D0
Fiscal year endsApril 30
SEC categoryemerging growth company, smaller reporting company
Data on record since2023

Share this section

Download image